BrainEver’s innovative therapeutic strategy is a translation of the work by Alain Prochiantz and colleagues on brain development and physiology. They demonstrated that homeoproteins, first identified as early developmental regulators, are also active throughout life and control several neuronal functions, including metabolism and epigeneticstability.BrainEver makes the hypothesis that, in patients, homeoprotein administration could durably modify the physiological resistance of surviving neurons while increasing their activity, thus leading to the improvement of clinical symptoms.Different homeoproteins that could be important in different neurodegenerative pathologies are being explored, the most advanced being Engrailed 1 (BREN01) for the treatment of Parkinson Disease and Amyotrophic Lateral Sclerosis (ALS).Beside Engrailed 1 in Parkinson Disease and ALS, BrainEver is currently generating a pipeline of 4 drug candidates targeting other neurodegenerative disease like Huntington Disease and Optic Neuropathies.

Biotechnology

BrainEver

The Paris office focuses on research and development in the scientific field, supporting innovation and operations.

Paris

BrainEver's headquarters in Saint-antoine, France

This department manages and oversees clinical research and operations to ensure effective and compliant study conduct.

Clinical Operations

This department focuses on innovation and the development of new products and technologies.

People (1)

Jobs (0)

Other teams

Research and Development